Dupont Jakob's Form 4 filing
Atara Biotherapeutics, Inc. (ATRA) · filed Nov 18, 2022
- Accession no.
- 0001140361-22-042381
- Filed
- Nov 18, 2022
- Trade date
- Nov 16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $19.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dupont JakobCIK 0001553335 | Officer (EVP, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
Referenced by the price of 2 transactions in Table I.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney